Among the 200 shares listed on the benchmark ASX 200 index are some of the highest quality companies that Australia has to offer. One of those is CSL Limited (ASX: CSL).
Why CSL shares?
CSL is widely regarded to be one of the highest quality shares on the ASX 200. It is a biotherapeutics company that develops, manufactures, and sells a range of life-saving plasma therapies and vaccines. It is also in the process of acquiring Vifor Pharma for ~$17 billion.
The addition of Vifor is expected to expand CSL’s leadership across an attractive portfolio focused on renal disease and iron deficiency, complementing its existing therapeutic focus areas including Haematology, Thrombosis, Cardiovascular, and Transplant.
But it doesn’t end there. Each year CSL invests in the region of 10% to 11% of its sales back into research and development (R&D) activities. In fact, earlier this month when the company released its half year results, it revealed an R&D spend of US$486 million for the six months. Pleasingly, CSL looks set to soon bear the fruit from its R&D labour. Management advised that a promising cluster of R&D programs are nearing completion.
Is the CSL share price good value?
The team at Morgans see a lot of value in the CSL share price. In response to its half year results, last week the broker put an add rating and $327.60 price target on its shares.
Based on the current CSL share price of $268.89, this implies potential upside of 22% for investors over the next 12 months.
It commented: “CSL – 1H above expectations; the “tide is beginning to turn” 1H results were better than expected, albeit in line with management’s assumptions, with net profit down 5% in cc on 4% revenue growth.”
“While near term challenges remain, the ongoing recovery in plasma collections, coupled with management’s confidence, paints a favourable earnings picture,” it concludes.
The post Here’s why CSL (ASX:CSL) could be an ASX 200 share to buy now appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
- ASX 200 shares stage comeback amid Russia optimism
- Own CSL shares? Boss reveals why biotech is ‘not fussed’ about exiting COVID vaccine race
- Top brokers name 3 ASX shares to buy next week
- 3 of the best results on the ASX 200 last week
- Why Challenger, CSL, NRW, and Woodside shares are pushing higher
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/qbYdJmR